Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
December 17, 2024 07:30 ET
|
Teva Pharmaceutical Industries Ltd
Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the...
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
December 11, 2024 08:00 ET
|
Teva Pharmaceutical Industries Ltd
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY,...
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 05, 2024 18:00 ET
|
Teva Pharmaceutical Industries Ltd
Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will...
Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE
December 04, 2024 08:10 ET
|
Teva Pharmaceutical Industries Ltd
AJOVY® (Fremanezumab) reduzierte die monatlichen Migränetage (MMD) und monatlichen Kopfschmerztage (MHD) im Vergleich zu Placebo über einen Zeitraum von 12 Wochen bei pädiatrischen Patienten im Alter...
Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE
December 04, 2024 08:10 ET
|
Teva Pharmaceutical Industries Ltd
AJOVY® (frémanézumab) a permis de réduire de manière significative le nombre de jours de migraine mensuels (MMD, de l’anglais « monthly migraine days ») et le nombre de jours de céphalées mensuels...
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
December 04, 2024 02:00 ET
|
Teva Pharmaceutical Industries Ltd
AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1Efficacy consistent...
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024 18:00 ET
|
Teva Pharmaceutical Industries Ltd
TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s...
Teva to Present at the Jefferies London Healthcare Conference
November 08, 2024 16:30 ET
|
Teva Pharmaceutical Industries Ltd
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
November 06, 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared...
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
November 01, 2024 15:05 ET
|
Teva Pharmaceutical Industries Ltd
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental...